Photocure, The Bladder Cancer Company, announces the full study publication by Meera R. Chappidi, et al. "Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons" in The Journal of Urology this month. This Photocure U.S. registry publication focusing on detection of bladder cancer recurrences after BCG treatment was first presented as an abstract at the SUO 2020 meeting.
The study objective was to determine if BLC improves recurrence detection in non-muscle invasive bladder cancer (NMIBC) patients undergoing BCG treatment. According to the authors, the utility of blue light cystoscopy (BLC) in patients receiving Bacillus Calmette Guerin (BCG) during post-treatment cystoscopy is not well understood.
The authors used the multi-institutional The Blue Light Cystoscopy with Cysview® Registry database, identifying all patients who received BCG within one year prior to BLC (282 procedures in total), looking at detection of recurrences and assessing detection with white light cystoscopy (WLC), blue light cystoscopy (BLC®) or both.
Key study results included: The overall recurrence rate was 45% (detection with BLC). Detection of recurrences with white light only in the same patients would have been 39.4% (n=111/282) instead of 45.0% (n=127/282) with BLC. Furthermore, without BLC, 12.6% (n=16/127) of the total recurrences would not have been detected.
In addition to concluding that BLC helped detect recurrences after recent BCG that would have been missed with WLC alone, the authors state: "As clinical trials of novel therapies for BCG unresponsive disease increase and there are no clear guidelines on BLC use for post-treatment cystoscopies, it is important to consider how variable BLC use could affect enrollment and comparisons of these studies."
Read the full study here: https://www.auajournals.org/doi/10.1097/JU.0000000000002308
The Blue Light Cystoscopy with Cysview® Registry (Clinicaltrials NCT02660645) is the largest bladder cancer registry in the U.S. It has enrolled more than 2000 patients with non-muscle invasive bladder cancer (NMIBC) since 2014, aiming at over 4000 patients, and is continuing to add more sites and generate data. The registry's purpose is to generate longitudinal, real-world evidence on the value of Blue Light Cystoscopy in the management of NMIBC, from patients who have received this treatment as an adjunct to white light cystoscopy. Sponsored by Photocure, the Blue Light Cystoscopy with Cysview Registry intends to add to the body of evidence supporting the procedure, with key objectives to produce more data and additional insights into Blue Light with Cysview including its impact on long-term clinical and patient-reported outcomes.